Astria Therapeutics (ATXS) 10-K2023 FY Annual report

Filed: 4 Mar 24, 4:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. senior Avg

New words: abide, abrocitinib, ADBRY, afucosylated, Akesobio, Amgen, Amlitelimab, anniversary, anti, Apogee, appeal, Arab, Arabia, arbitrarily, arbitrary, archived, Argentina, artificial, Asia, Aslan, AstraZeneca, atopic, Australia, autoimmune, awaiting, background, bad, barrier, Bayer, bearing, Beck, bempikibart, billion, Bio, biomarker, Biopharma, Biosion, biotech, Boehringer, boost, Brazil, Bristol, Canadian, capriciously, cascade, CDMO, cellular, certiorari, Chamber, Chile, Chinese, CIBINQO, CIBINQOTM, comfort, compelled, conservative, Council, Creek, cultural, culture, customary, cytotoxicity, Dakota, de, delegated, destined, digital, disagreement, donor, Duck, dupilumab, DUPIXENT, durable, East, eblasakimab, effector, Eli, engineered, entrench, etrasimod, exemplify, fifteen, forthcoming, France, freestanding, Galderma, Germany, GSK, heterogenicity, highest, HTA, immune, inflammatory, Ingelheim, Inmagene, InnoCare, instrument, intelligence, ISB, Israel, Italy, itching, JAK, Janssen, Japan, Jersey, Joanne, kickback, kinase, Kirin, Korea, Kuwait, Kymera, Kyowa, lebrikizumab, led, LEO, ligand, Lilly, MA, MAs, mechanism, MEPT, Merck, mg, Middle, mifepristone, missing, misuse, navigate, Nektar, nemolizumab, Nevada, Nordisk, Novo, OLUMIAN, OLUMIANT, onsite, Parliament, payer, petition, Pfizer, Pharma, PhRMA, plaintiff, predetermined, preparatory, principle, proliferation, rademikibart, RAPT, regular, reinstated, relapse, relaxation, relocate, rezpegaldesleukin, rilzabrutinib, RINVOQ, Road, rocatinlimab, runway, SA, Sanofi, Saudi, scarce, Seaport, sequence, simulate, South, Spain, spanning, sparing, spectrum, Squibb, stalled, stance, stay, stayed, strongly, sue, surgical, Switzerland, takeover, telazorlimab, tenant, terrorism, theft, tiered, transposed, truthful, turn, unbiased, uncompensated, unexercised, unique, upadacitinib, upfront, upstream, urticaria, Vice, vigilance, vigilant, Washington, Wharf, Windsor, Wisconsin, writ, zabedosertib

Removed: accredited, Assent, assumed, CAA, carryback, CAT, competitively, converting, COSO, Cowen, discounted, DOJ, DSMB, Duchenne, dystrophy, edasalonexent, FCPA, FFCR, freedom, GalaxyDMD, harmful, HITECH, Irish, left, MAA, marked, mission, monkey, muscular, NIH, outbreak, PolarisDMD, presidential, quickly, regulator, reliant, restructuring, Royal, Senate, split, stopped, stopping, sublicensing, suspended, threatening, translate, unaffected, unambiguously

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ATXS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Annual Report on Form 10-K of Astria Therapeutics, Inc. (the “Company”) for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Noah C. Clauser, Chief Financial Officer and Treasurer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that, to his knowledge on the date hereof:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: March 4, 2024
	/s/ Noah C. Clauser
	Noah C. Clauser
	Chief Financial Officer and Treasurer
	(Principal Financial Officer)